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Background: There are conflicting data on the role of a patent foramen ovale (PFO) in the pathogenesis of
cryptogenic stroke. The aim of this study was to evaluate the incidence of cerebrovascular events associated
with PFO in a large population of patients during mid-term follow-up.
Methods and results:We prospectively investigated 446 consecutive patients (58% female, age 50±14 years) in
whom PFOwas detected by contrast echocardiography following cryptogenic stroke (30.5%), transient ischemic
attack (TIA, 23.7%), migraine(10.5%) or evaluation for other cardiac diseases(35%). Prevalence of other clinical
conditions potentially associated with cerebral embolism, such as mitral valve disease, atrial fibrillation and
aortic atherosclerosis were 31%, 12.5%, 11.2%, respectively; 99 out of 446 patients (22%, group 1) underwent PFO
closure, shortly after diagnosis, while 347 (78%, group 2) received only medical therapy (antiplatelet drugs and
vitamin K antagonists). During 54 months (range 12–96) of average follow-up few events had been observed:
one fatal stroke (1%) in group 1 and 3 nonfatal strokes (0.86%) in group 2 (not significant); thereweremore TIAs
in group 1 than in group 2 (5, 5% versus 3, 0.86%, p=0.02): 8/12 new cerebrovascular events occurred in
patients with previous cerebral ischemia and in 7/12 there were other cardioembolic sources. Kaplan–Meier
survival free from cerebrovascular events showed a slightly better prognosis in unclosed PFO patients compared
to closed PFO ones, statistically significant (p=0.004).
Conclusions: New cerebrovascular events are rare in unselected subjects with PFO, even in those with previous
cerebral ischemia and those who have not undergone PFO closure, with an event rate similar to that observed in
the general population.
© 2010 Elsevier Ireland Ltd. All rights reserved.1. Introduction
The etiology of ischemic stroke remains undetermined in up to 40%
of patients (pts) affected, despite an extensive diagnostic evaluation.
Stroke is referred to as cryptogenic (CS) [1]. A role for patent foramen
ovale (PFO) in the pathogenesis of CS, in particular in pts younger than
55 years, has been hypothesized. A statistically significant associationtogenic stroke; CVEs, cerebro-
foramen ovale; TIA, transient
ali Civili, P.zza Spedali Civili 1;
303995013.
Ltd. All rights reserved.between PFO and CS has been reported in several case–control
studies, showing a higher prevalence of PFO among stroke pts
compared to stroke-free controls [2,3]. Furthermore, a meta-analysis
of all case–control reports [4] and a recent large prospective study [5]
seem to support this association.
However, a cause–effect relationship between PFO and CS has not
been convincingly demonstrated; in particular, the extent of the PFO-
related stroke risk in the general population still remains controver-
sial [6]. Furthermore, several studies have consistently found that the
presence of a PFO does not inherently increase the risk of recurrent
stroke [7–10]. Finally, two large prospective studies recently pub-
lished showed a very low rate of first cerebrovascular events in
asymptomatic subjects with PFO [11,12].
Treatment options for secondary prevention of recurrent stroke in
pts with CS and PFO include medical therapy with antiplatelet agents
Table 1




Sex (M/F) 187/259 (42%/58%)
Age 50±14 years (15–81)
≤55 years 264 (59%)
Indication to PFO detection
Cryptogenic stroke 136 (30.5%)
TIA 106 (23.7%)
Migraine 47 (10.5%)
Occasional detection 157 (35%)
Echocardiographic characteristics
Atrial septal aneurism 117 (26.2%)
PFO tunnel like 21 (4.7%)
Shunt at rest 138 (31%)
Shunt during Valsalva maneuver 299 (67%)
Severe shunt 47 (10.5%)
Associated features
Thoracic aorta atherosclerosis 50 (11.2%)
Atrial fibrillation 56 (12.5%)
Mitral valve disease 138 (31%)
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The choice of the best therapeutic approach is still a matter of intense
debate. The main reason is the lack of published randomized clinical
trials comparing the efficacy and safety of percutaneous/surgical
closure and those of conventional medical therapy [13]. Given the
limited and conflicting data existing in literature, both the American
Heart Association/American Stroke Association (AHA/ASA) [14] and
the American College of Chest Physicians (ACCP) [15] guidelines
recommend antiplatelet therapy for patients with ischemic stroke or
transient ischemic attack and PFO (AHA/ASA class IIa, Evidence B;
ACCP grade 1A), unless other indications exist for vitamin K
antagonist therapy (AHA/ASA class IIa, Evidence C; ACCP grade 1C),
and state that PFO closuremay only be considered for patients with CS
recurrence despite optimal medical therapy (class IIb, evidence C)
[14,16].
Accordingly, the aim of the present study was to prospectively
evaluate the rate of cerebrovascular events, during a mean follow-up
period of 4.5 years, associated with the presence of a PFO in a large
population of pts, in whom PFO has been detected, and eventually
closed, for different clinical indications.
2. Methods
From January 2000 to January 2008 we prospectively evaluated 446 pts
consecutively referred to Echo Lab of Cardiology Division, Spedali Civili Brescia, and
Camposanpiero Hospital in whom PFO was detected. Indications for referral were:
history of cryptogenic stroke (CS) or transient ischemic attack (TIA), migraine,
Doppler-echocardiographic evaluation of other cardiac diseases. The diagnosis of PFO
was made by contrast echocardiography in all subjects (see later discussion).
2.1. Echocardiographic evaluation
Transthoracic and transesophageal echocardiographies were performed with
commercially available instruments according to standard practice guidelines [17–
19]. A PFO was defined as a right-to-left interatrial shunt found during intravenous
injection of agitated saline at rest and/or at the end of Valsalva maneuver in all patients.
The severity of the shunt was considered mild to moderate or severe on the basis of
bubbles number passing through the hole (≤10 versus N10 bubbles, respectively),
respectively. Visualization of a “hole” only was not sufficient for diagnosis of PFO. Atrial
septal aneurysm (ASA) was defined according to criteria previously published by
Agmon et al. [19] and Hanley et al. [20]: 1) diameter of the base of the aneurismal
portion of the interatrial septum (IAS) 15 mm or more and either 2) protrusion of the
IAS, or part of it, 15 mm or more beyond the plane of the IAS or 3) phasic excursion of
the IAS during the cardiorespiratory cycle 15 mm or more in total amplitude. The heart
and thoracic aorta were scanned for the presence of potential embolism sources, such
as valve or myocardial diseases, thrombus or protruding atherosclerotic plaque [21].
2.2. Assessment of prothrombotic status
Analysis for inherited prothrombotic defects, such as prothrombin G20210A
mutation, factor V Leiden G1691A mutation, C protein, S protein and antithrombin III
deficiency, was available in 165 subjects ≤55 years. Furthermore, in the same patients,
the search for thrombophilic conditions, such as connective tissue diseases, antipho-
spholipid antibody syndrome and lupus erythematosus, was also made. Oral
anticoagulant and antiplatelet therapy was recorded.
The therapeutic decisions, either drug therapy alone or combined with PFO closure,
based on clinical picture and echocardiographic results, were in charge of Neurologist
or Cardiologist or Family Physicians caring for the pts. No author of the present study
was actively involved in the decision-making process.
2.3. Follow-up
All patients were followed up prospectively for a mean period of 54 months (range
12 to 96 months) by annual phone call and/or clinical evaluation. Any vascular event or
acknowledgment of neurological or cardiac symptoms during the annual standardized
interview triggered an in-person assessment. All patients with suspected new
cerebrovascular events were clinically examined by a Neurologist and, whenever
indicated, underwent an imaging non-invasive study, i.e. brain magnetic resonance
imaging or computed tomography.
2.4. Analysis of events
Cerebrovascular events (CVEs) considered were transient ischemic attack, cerebral
infarct, or death as the result of the aforementioned conditions. Other eventsconsidered were total mortality, cardiovascular events (pulmonary or peripheral
embolism, myocardial infarction) and neurologic symptoms not attributed to cerebral
ischemia.
All pts gave written informed consent to participate, and Hospital Ethical
Committee approved the study.2.5. Statistical analysis
The demographic and clinical variables were expressed as mean values±standard
deviation (SD). Mann–Whitney and Chi-square analyses assessed the differences in
continuous and in categorical variables, respectively. Survival free from fatal and
nonfatal cerebrovascular events for PFO closed and PFO not closed pts was analyzed
using Kaplan–Meier cumulative curves. Survival curves were compared using the log-
rank test. All analyses were performed using SPSS, version 16.1 software (CHICAGO, IL,
USA).3. Results
3.1. Study population
The demographic, clinical and echocardiographic characteristics of
pts included in the study are summarized in Table 1. The most
common indication for detection of PFO was represented by recent or
remote cerebrovascular events which accounted for more than one
half of all pts (54.2%: CS in 30.5% and TIAs in 23.7%), followed by an
occasional finding during echocardiographic examination performed
for other cardiac diseases in approximately one third (35%) and
migraine in the remaining 10.5% of the entire study group. ASA
associated with PFO was found in more than one fourth of all pts, and
a large right-to-left shunt was relatively common (10.5%). Of interest,
clinical conditions potentially associated with cerebral or peripheral
embolism, such as mitral valve disease, atrial fibrillation and aortic
atherosclerosis were relatively common (Table 1) and several pts
showed 2 or more potential causes of cerebral ischemia
simultaneously.
Four out of 165 pts ≤55 years, in whom prothrombotic status was
assessed, had some inherited defects: 2 pts had prothrombin
mutation, 1 patient had factor V Leiden Mutation and another 1 had
antithrombin deficiency. Some prothrombotic conditions were iden-
tified in eight patients: 2 pts had systemic scleroderma, 3 had
antiphospholipid antibodies syndrome, 1 patient had lupus erythe-
matosus, another one vasculitis and a third one undifferentiated
connective tissue disease.
Table 2




Group 2 (PFO not
closed) n=347
p






≤55 years 66 (66.6%) 198 (57%) ns
Clinical features
Aortic atherosclerosis 6 (6%) 44 (12.6%) 0.09
Atrial fibrillation 2 (2%) 54 (15.5%) b0.001
Mitral valvular disease 26 (26%) 112 (32.2%) ns
Echocardiography
ASA 32 (32%) 85 (24.5%) ns
PFO tunnel like 9 (9%) 12 (3.4%) 0.04
Shunt at rest 51 (51%) 87 (25%) b0.001
Shunt during Valsalva
maneuver
95 (95%) 204 (58.7%) b0.001
Severe shunt 24 (24%) 23 (6.6%) b0.001
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After the result of clinical, laboratory and echocardiographic
examinations, antiplatelet drugs or vitamin K antagonists were
prescribed from physicians responsible for care of pts to 228 (51%)
and 45 (10%) subjects, respectively. Shortly after recognition of PFO,
99 out of 446 pts (22%, group 1) underwent PFO closure, percutaneous
[91 pts] or surgical [8 pts], while 347 pts (78%, group 2) only received
conventional medical therapy. The clinical indications for closure are
indicated in Fig. 1. Only 11 out of 99 pts sent to PFO closure (11%) had
a recurrent ischemic event (3 strokes and 8 TIAs), all before initial PFO
detection, and, hence, an accepted indication for PFO closure,
according to current guidelines [13,14,22,23]. Characteristics of pts
with (group 1) and without PFO closure (group 2) are shown in
Table 2. Atrial fibrillation was significantly most common in those pts
not sent to PFO closure. As expected, echocardiographic indicators of
larger PFO, such as shunt at rest and severe shunt, were significantly
most common in those pts sent to closure. Furthermore, there was no
significant difference in the initial clinical presentation (CS, TIA,
migraine or occasional detection) between the two groups.
Mean duration of follow-up was 54±20months (range 12 to
96 months). The rate of events occurring during follow-up is reported
in Table 3. There have been 10 deaths (2.2%) during the follow-up, 1 in
group 1 (PFO closed), as a consequence of ischemic stroke, and 9 in
group 2 (PFO not closed), due to metastatic cancer (4 pts), cerebral
bleeding due to head trauma (1 pt), chronic heart failure (2 pts) and
unknown mechanism (2 pts). Regarding cerebrovascular events, 3
nonfatal ischemic strokes (0.86%) were observed in group 2, in addition
to one fatal ischemic stroke (1%) in group 1 (difference not significant).
Incidence of TIAs was higher in group 1 (5 pts, 5%, versus 3 pts, 0.8%;
Table 3). Clinical features of pts with cerebrovascular events are
described in Table 4. Of interest, 7 out of 12 pts had one or more
abnormalities, such as atrial fibrillation, mitral valve disease or aortic
atherosclerosis, potentially responsible for cerebral ischemia, in
alternative to PFO.
None of the 4 pts with prothrombotic defects presented a
cerebrovascular event during follow-up. Among 8 pts with pro-
thrombotic conditions, only a fifty-eight year old woman, who was
affected by lupus erythematosus, on antiplatelet therapy and included
in group 2, had recurrent TIAs. Finally, the incidence of other events,
such as pulmonary or peripheral embolism, endocarditis and minor
aspecific neurologic symptoms, occurred during the follow-up, are
presented in Table 3.Fig. 1. Indications for PFO closure in 99Fig. 2 shows the Kaplan–Meier analysis of survival free from
cerebrovascular events during follow-up: pts without PFO closure
showed a statistically significant better prognosis, in comparison to
those who underwent PFO closure, i.e. survival at 1, 3 and 5 years:
97.3%, 92.6%, 89.4% in group 1 versus 99.8%, 99.3% 97.8% in group 2,
respectively (p=0.004).
4. Discussion
The main result of this study, performed on a large population of
subjects with PFO, during a mean follow-up of more than four years,
indicates a low rate of new cerebrovascular events (fatal and non fatal
stroke, TIAs), that is 12 in 446 pts (2.7%), corresponding to a stroke
and TIA annual incidence of ~0.2% and ~0.4% respectively. Incidence of
cerebrovascular events resulted roughly similar in pts with closed PFO
(group 1) and in pts with not closed PFO (group 2). Survival free from
cerebrovascular events was higher in group 2 pts (PFO not closed) at
Kaplan–Meyer analysis.
Although a statistically significant association between PFO and CS
has been demonstrated in the past, mostly through case–control
studies showing a higher prevalence of PFO among stroke pts
compared to stroke-free controls [2–4], however, a clear cause–effectpts (group 1). See text for details.
Table 3










Death 10 (2.2%) 1 (1%) 9 (2.6%) 0.58
TIA 8 (1.8%) 5 (5%) 3 (0.8%) 0.02
Stroke 4 (0.9%) 1 (1%) 3 (0.86%) 0.63
Fatal Stroke 1 (0.2%) 1 (1%) 0 0.50
Non fatal Stroke 3 (0.6%) 0 3 (0.8%) 0.81
Endocarditis 1 (0.22%) 1 (1%) 0 0.50
Peripheral embolism 1 (0.22%) 1 (1%) 0 0.50
Pulmonary embolism 1 (0.22%) 0 1 (0.28%) 0.50
Aspecific neurological
symptoms
7 (1.5%) 5 (5%) 2 (0.5%) 0.007
Fig. 2. Kaplan–Meier analysis of survival free from cerebrovascular events during
follow-up. See text for details.
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remains controversial [6,24]. Initial studies that documented an
increased risk of stroke related to the presence of PFOwere conducted
on pts at increased risk of stroke, either because they had previous
stroke [1–4,25] or because of associated abnormalities or morbid
conditions, such as ASA and/or large size of PFO-related shunt [26–
28], the presence of deep venous thrombosis [29,30], right atrial
abnormalities [31] and hypercoagulability [32–35]. On the other hand,
data obtained from 2 prospective population-based cohort studies
suggested a low risk of first stroke among pts with PFO [11,12]. In the
NorthernManhattan Study (NOMAS), presence of PFOwas not related
to an increased stroke risk in a multiethnic cohort of both men and
women: stroke incidence was 12.2 per 1000 person-years in subjects
with a PFO and 8.9 per 1000 person-years in those without it
(difference not significant). Furthermore, the frequency of stroke in
the general population was considered low (6.2% during a median
follow-up of ~6.5 years, corresponding to annual incidence rate of
~1%) [11]. Again, PFO was not an independent predictor of stroke
among subjects older than 45 years of age in the SPARC study: the
adjusted PFO-related hazard ratio of cerebrovascular events was 1.46
(95% CI 0.74 to 2.88)[12]. Similar conclusions on the PFO-related
stroke risk were drawn by the same investigators using a case–control
design [36].
In addition, several studies have consistently found that the
presence of a PFO does not increase the risk of recurrent stroke. The
best data concerning PFO and stroke recurrence come from 3
prospective cohort studies [7–9]. None of these studies found an
increased risk of recurrent stroke in pts with a PFO compared with
those without PFO, and a pooled analysis of the 3 studies reported a
relative risk of 0.95 (95% CI, 0.62 to 1.44) [10].
Of interest, in our study, which included both subjects with and
without previous cerebral ischemia, the stroke rate (first event or
recurrence) during follow-up was respectively 1% in subjects withTable 4
Characteristics of patients with cerebrovascular events during follow-up.
Pt Age/sex Initial clinical presentation ASA Atrial fib.
Group 1 M.C. 54/M Stroke No No
T.M. 43/F Stroke No No
N.G 30/M TIA No No
C.M. 70/F Stroke Yes No
N.E. 33/M TIA No No
P.F. 59/M Occasional Yes No
Group 2 F.L. 33/M TIA Yes No
L.M. 76/F Stroke No No
C.A. 76/F Occasional No Yes
S.V. 58/F Stroke No No
G.M 75/M Occasional No No
D.B 80/M Occasional Yes Yesclosed PFO and 0.8% in those with unclosed PFO (difference not
significant), with a stroke risk comparable to the one estimated in the
general population (≈1%per year) [37,38].
An important issue that should be emphasized is the large
eterogeneity observed in this study in the decision to close the PFO
(illustrated in Fig. 1), reflecting the different opinions of physicians
caring for pts and their adherence to current guidelines: most pts
(89%) underwent PFO closure after the first cerebrovascular event, or
for migraine or for primary prevention in occasionally detected PFO,
conditions for which there is no published evidence that surgical/
percutaneous PFO treatment improves prognosis [39,40]. On the other
hand, only 11% of group 1 pts had an accepted indication to PFO
closure, that is recurrent stroke or TIA despite medical therapy, as
recommended by published guidelines [14,15]. However, despite the
nonrandomized design of this study, follow-up of our pts showed few
events not only in group 1 pts but also, and specially, in group 2 pts, in
whom TIAs were even less common. Furthermore, survival free from
cerebrovascular events was significantly better in group 2 compared
to group 1 pts (Fig. 2).
These data support the need for prospective randomized studies
comparing the effects of conventional medical therapy and PFO
closure on prognosis in selected group of pts with “symptomatic” PFO
[13,41].
Another point of interest is represented from the presence, inmore
than half of our pts with cerebrovascular events (7 out of 12, 58%)
during follow-up, of other clinical and echocardiographic features
potentially responsible for cardioembolism, such as atrial fibrillation,
mitral valve disease, thoracic aortic atherosclerosis, in alternative to
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treatment in preventing new cerebrovascular events and for selecting
the appropriate therapeutic option.
5. Study limitations
First of all, the cohort evaluated in this studywas heterogeneous as
far as neurological diseases. There were some patients with stroke,
some with TIA, others with migraine and some with no neurological
disease, but with various cardiac diseases. However, these patients
represent a general population consecutively referred to Echo Lab and
resulted to be affected by PFO.
We do recognize that the inclusion of TIA as an endpoint may be
misleading, since it is difficult to be evaluated – even by the
neurologist – especially by an annual phone call survey.
Furthermore, this study had a prospective non randomized design,
with pts consecutively enrolled following recognition of PFO during
echocardiographic examination performed for different clinical
indications. Pts included were different for clinical presentation and
therapeutic choices (closure or medical treatment), the latter left to
experience and preferences of personal physicians and not reflecting
an evidence-based approach, as opposed to a randomized trial.
Most patients were on treatment with antiplatelet drugs or
vitamin K antagonists, according to physicians decisions and not a
per protocol approach. Due to the small number of pts with
prothrombotic defect or conditions, we could not assess the clinical
relevance of their association with PFO. However, the role of
thrombophilia in pathogenesis of ischemic stroke is still controversial
[46].
Therefore, the results of the follow-up may be biased, if compared
to the results of randomized studies. However, to date no randomized
clinical trials comparing the effects of conventional medical therapy
and PFO closure have been completed and published.
Hence, our data provide, in our opinion, relevant insights on
treatment and outcomes of PFO subjects from the “real world”, while
waiting for the results of ongoing studies.
6. Conclusions
Our study suggests that new cerebrovascular events are rare in
unselected subjects with PFO, even in those with previous cerebral
ischemia and in those who have not undergone PFO closure, with an
event rate very similar to the one observed in general population.
These data confirm recent evidence from other observational studies,
which lead to reconsider the need for PFO closure. Considering the
relevant therapeutic implications, these data require confirmation in
ongoing, prospective, randomized clinical trials.
6.1. Addendum
Preliminary results of the CLOSURE I trial have been recently
released. The trial failed to achieve its primary endpoint and PFO
closure, using the Starflex device, was not superior to the best medical
therapy for preventing recurrent stroke or TIA [47].
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